Synonyms for ohss or Related words with ohss
Examples of "ohss"
In mild forms of
the ovaries are enlarged (5–12 cm) and there may be additional accumulation of ascites with mild abdominal distension, abdominal pain, nausea, and diarrhea. In severe forms of
there may be hemoconcentration, thrombosis, distension, oliguria (decreased urine production), pleural effusion, and respiratory distress. Early
develops before pregnancy testing and late
is seen in early pregnancy.
depends on the severity of the hyperstimulation.
The hyperstimulation of the ovaries in practices like IVF can result in mild "ovarian hyperstimulation syndrome" (
) in more than 20% of cases. This same hyperstimulation can cause severe
in up to 2% of cases.
can have serious consequences, including respiratory problems, renal impairment and even stroke.
can be treated conservatively with monitoring of abdominal girth, weight, and discomfort on an outpatient basis until either conception or menstruation occurs. Conception can cause mild
to worsen in severity.
is divided into the categories mild, moderate, severe, and critical.
Final maturation induction using GnRH agonist results in a substantial decrease in the risk of ovarian hyperstimulation syndrome (
). A Cochrane review estimated that using GnRH agonist instead of hCG in IVF decreases the risk of mild, moderate or severe
with an odds ratio of approximately 0.15. The review estimated that, for a woman with a 5% risk of mild, moderate or severe
with the use of HCG, the risk of
with the use of a GnRH agonist would be between 0 and 2%.
Cabergoline confers a significant reduction in the risk of
in high risk women according to a Cochrane review of randomized studies, but the included trials did not report the live birth rates or multiple pregnancy rates. Cabergoline, as well as other dopamine agonists, might reduce the severity of
by interfering with the VEGF system. A systematic review and meta-analysis concluded that prophylactic treatment with cabergoline reduces the incidence, but not the severity of
, without compromising pregnancy outcomes.
A Cochrane review found administration of hydroxyethyl starch decreases the incidence of severe
. There was insufﬁcient evidence to support routine cryopreservation and insufﬁcient evidence for the relative merits of intravenous albumin versus cryopreservation. Also, "coasting", which is ovarian hyperstimulation without induction of final maturation, does not significantly decrease the risk of
Criteria for severe
include enlarged ovary, ascites, hematocrit > 45%, WBC > 15,000, oliguria, creatinine 1.0-1.5 mg/dl, creatinine clearance > 50 ml/min, liver dysfunction, and anasarca. Critical
includes enlarged ovary, tense ascites with hydrothorax and pericardial effusion, hematocrit > 55%, WBC > 25,000, oligoanuria, creatinine > 1.6 mg/dl, creatinine clearance < 50 ml/min, renal failure, thromboembolic phenomena, and ARDS.
has been characterized by the presence of multiple luteinized cysts within the ovaries leading to ovarian enlargement and secondary complications, but that definition includes almost all women undergoing ovarian stimulation. The central feature of clinically significant
is the development of vascular hyperpermeability and the resulting shift of fluids into the third space.
Physicians can reduce the risk of
by monitoring of FSH therapy to use this medication judiciously, and by withholding hCG medication.
There is no evidence for an increased risk of ovarian hyperstimulation syndrome (
) with IVF when compared with ovarian stimulation combined with IUI.
There is a concomitant monitoring, including frequently checking the estradiol level and, by means of gynecologic ultrasonography, follicular growth. Cycle monitoring by ultrasound plus serum estradiol compared to monitoring by ultrasound only does not increase live birth or pregnancy rates, but may be useful in preventing ovarian hyperstimulation syndrome (
), and may therefore be a used in a subset of women to identify those at high risk of
may be complicated by ovarian torsion, ovarian rupture, thrombophlebitis and renal insufficiency. Symptoms generally resolve in 1 to 2 weeks, but will be more severe and persist longer if pregnancy occurs. This is due to human chorionic gonadotropin (hCG) from the pregnancy acting on the corpus luteum in the ovaries in sustaining the pregnancy before the placenta has fully developed. Typically, even in severe
with a developing pregnancy, the duration does not exceed the first trimester.
"Coasting", which is ovarian hyperstimulation without induction of final maturation, does not significantly decrease the risk of ovarian hyperstimulation syndrome (
), according to a Cochrane review of randomized trials.
Patients with PCOS and younger women are at an increased risk of
. In these women, it may be even more beneficial to employ IVM rather than conventional IVF treatment.
Ovarian hyperstimulation syndrome (
) is a medical condition affecting the ovaries of some women who take fertility medication to stimulate egg growth. Most cases are mild, but rarely the condition is severe and can lead to serious illness or death.
is very rare, and may have a genetic component. Clomifene citrate therapy can occasionally lead to
, but the vast majority of cases develop after use of gonadotropin therapy (with administration of FSH), such as Pergonal, and administration of hCG to induce final oocyte maturation and/or trigger oocyte release, often in conjunction with IVF. The frequency varies and depends on a woman's risk factors, management, and methods of surveillance. About 5% of treated women may encounter moderate to severe
. Risk factors include young age, the development of many ovarian follicles under stimulation, extreme elevated serum estradiol concentrations, the use of hCG for final oocyte maturation and/or release, the continued use of hCG for luteal support, and the occurrence of a pregnancy (resulting in hCG production).
According to Jansen and Tucker, writing in the same ART (assisted reproductive technologies) textbook referenced above, the risk of
varies with the clinic administering the hormones, from 6.6 to 8.4% of cycles, half of them "severe." The most severe form of
is life-threatening. Recent studies have found that donors were at less risk of
when the final maturation of oocytes was induced by GnRH agonist than with recombinant hCG. Both hormones were comparable in the number of mature oocytes produced and fertilization rates. A larger study in the Netherlands found 10 documented cases of deaths from IVF, with a rate of 1:10,000. "All of these patients were treated with GnRH agonists and none of these cases have been published in the scientific literature."
typically requires interrupting the pathological sequence, such as avoiding the use of hCG. One alternative is to use a GnRH agonist instead of hCG. While this has been repeatedly shown to "virtually eliminate"
risk, there is some controversy regarding the effect on pregnancy rates if a fresh non-donor embryo transfer is attempted, almost certainly due to a luteal phase defect. There is no dispute that the GnRH agonist trigger is effective for oocyte donors and for embryo banking (cryopreservation) cycles.
Copyright © 2017